Steven Templeton, Ph.D

Institution: Indiana University

Project: Adiponectin-Mediated Inhibition of Detrimental Inflammation in Invasive Aspergillosis

Grant(s): Innovation Award

Many patients with chronic diseases that affect lung function may require a lung transplant. These patients receive long-term immune suppressive therapy to prevent organ rejection and manage detrimental inflammation. However, these drugs render patients susceptible to "opportunistic" lung infections, including fungal infections such as the highly fatal invasive aspergillosis (IA). Current drugs to treat IA are limited, drug resistance is increasing and residual immune responses may cause further lung damage. In our preliminary studies, we identified a novel protective role for the protein hormone adiponectin in IA. We will study adiponectin-mediated inhibition of detrimental inflammation in IA. In addition, we will assess the ability of a new adiponectin receptor-binding drug, AdipoRon, to dampen inflammation and improve survival in infected mice. Our proposed work will identify novel targets with therapeutic potential and open new avenues of research in the development of detrimental immunity to infection.

Transgender Cultural Fluency & LGBTQ+ Lung Health Disparities
, | Jun 14, 2021
A Breath of Knowledge: A Lung Cancer Series for Healthcare Providers and Professionals – Session 4
, | Jun 15, 2021